Dr. Akhil Chopra

Qualification and Experience

Dr. Chopra completed his medical school training at Delhi University, India, in 2001, and later pursued fellowship training in Hematology and Medical Oncology at Hahnemann University Hospital/Drexel University College of Medicine in Philadelphia, USA. He holds American Board certifications in Internal Medicine, Hematology, and Medical Oncology and currently serves as a Senior Consultant at Johns Hopkins Singapore and Tan Tock Seng Hospital.

With extensive experience, Dr. Chopra specializes in treating various cancer types, including lung, breast, stomach, colon, rectum, liver, prostate, kidney, testicular, and bladder cancers, as well as gynecological cancers such as ovarian and uterine/cervical cancers. He also handles lymphomas, chronic leukemias, multiple myeloma, and rare cancers like sarcoma and neuroendocrine tumors.

As a senior specialist in cancer medicine, Dr. Chopra has managed patients globally, from India, the USA, Europe, the Middle East, Bangladesh, Vietnam, Myanmar, Cambodia, Malaysia, to Indonesia. He has been a principal researcher for various clinical trials involving immunotherapy agents across multiple tumor types. Dr. Chopra has co-authored a significant publication in the 'Lancet' regarding a clinical liver cancer trial and contributed to research on advanced nasopharyngeal carcinoma, lung, prostate, and kidney cancer treatments.

Beyond his clinical work, Dr. Chopra is involved in medical education, teaching students from the Lee Kong Chian School of Medicine, as well as medical residents and students from Johns Hopkins University, Baltimore, USA. He served as the Program Director for the National Health Care Group Medical Oncology from 2012 to 2017. Dr. Chopra is registered with the Singapore Medical Council under license number M014595E.

Areas of Interest

• Lung cancer
• Breast cancer
• Stomach cancer
• Rectum, liver, prostate, kidney, testicular and bladder cancer.

Contribution to Medical Science

Dr. Chopra is a contributing author in a clinical trial conducted across multiple regional cancer centers, focusing on liver cancer (hepatocellular carcinoma). Published in the esteemed journal Lancet, the trial explores the early utilization of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, for patients with advanced hepatocellular carcinoma, regardless of chronic viral hepatitis (CheckMate 040 trial).

Additionally, Dr. Chopra is a co-author of a significant publication in the Journal of Clinical Oncology, which investigates the role of nivolumab in advanced nasopharyngeal carcinoma, a prevalent cancer in Southeast Asia.

His extensive research contributions also encompass various publications delving into the treatment of lung, prostate, and kidney cancer.

Qualification

• MBBS: University of Delhi; India;2001
• Board Certified, Internal Medicine, The American Board of Internal Medicine
• Board Certified, Hematology, The American Board of Internal Medicine
• Board Certified, Medical Oncology, The American Board of Internal Medicine